SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 112.21 |
Enterprise Value ($M) | 90.55 |
Book Value ($M) | 104.44 |
Book Value / Share | 1.56 |
Price / Book | 1.07 |
NCAV ($M) | 46.91 |
NCAV / Share | 0.70 |
Price / NCAV | 2.39 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.73 |
Return on Assets (ROA) | -0.38 |
Return on Equity (ROE) | -0.63 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 6.34 |
Current Ratio | 6.34 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 191.25 |
Assets | 248.78 |
Liabilities | 144.34 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Price T Rowe Associates Inc /md/ | 14.00 | 35.02 | |
13G | BlackRock, Inc. | 5.10 | 0.00 | |
13G/A | Bb Biotech Ag | 5.50 | 0.00 | |
13G/A | Fmr Llc | 8.10 | -18.45 | |
13G/A | Atlas Venture Fund X, L.P. | 10.80 | 0.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
39,953 | 194,319 | 20.56 | |
52,494 | 179,743 | 29.21 | |
44,445 | 226,909 | 19.59 | |
48,917 | 193,556 | 25.27 | |
(click for more detail) |
Similar Companies | |
---|---|
EXEL – Exelixis, Inc. | FDMT – 4D Molecular Therapeutics, Inc. |
FGEN – FibroGen, Inc. | GERN – Geron Corporation |
GILD – Gilead Sciences, Inc. |
Financial data and stock pages provided by
Fintel.io